Search

A recent study conducted by researchers from Universitas Padjadjaran has developed an aptasensor using cerium oxide nanoparticles to detect chronic myeloid leukemia (CML) cells. CML is a highly lethal form of leukemia that requires effective diagnostic strategies. The aptasensor demonstrated good performance with a limit of detection of 16 cells/mL and a limit of quantification of 3,882 cells/mL in the concentration range of 102 to 106 cells/mL. These findings have the potential to contribute to the development of point-of-care devices for CML detection. [Extracted from the article]

A recent study conducted at Ohio State University explores the issue of acquired drug resistance in leukemia cells. The researchers focused on DNA topoisomerase IIa (TOP2a), an enzyme that plays a crucial role in chromosome separation and is targeted by anticancer drugs like etoposide. The study found that blocking or mutating a specific region of the TOP2a gene in drug-resistant leukemia cells restored sensitivity to TOP2a-targeting drugs. These findings suggest a potential strategy for overcoming drug resistance in leukemia treatment. [Extracted from the article]

Researchers from the State University of New York (SUNY) Buffalo have developed a systematic strategy for identifying the causal single nucleotide polymorphisms (SNPs) and their target genes on risk haplotypes for juvenile rheumatoid arthritis (JIA). The study used a function-based approach, including a massively parallel reporter assay (MPRA) and CRISPRi, to identify expression-altering SNPs and their associated genes. The findings suggest that JIA risk haplotypes can be analyzed to identify potential disease-driving variants and their target genes, which could lead to improved clinical care for JIA patients. The research was funded by the National Institutes of Health and the National Center for Advancing Translational Sciences. [Extracted from the article]

A study conducted by researchers at Dalian Medical University in China has investigated the effects of the ETV6-MECOM fusion gene on leukemia progression. The study found that the ETV6-MECOM oncoprotein promotes epithelial-to-mesenchymal transition (EMT) traits in leukemia cells, leading to increased cell migration, invasion, and sphere formation. The oncoprotein represses the transactivation activity of the E-cadherin promoter, resulting in the downregulation of E-cadherin expression. These findings could potentially contribute to the development of therapeutic targets for patients with myeloid leukemia characterized by ETV6-MECOM. [Extracted from the article]

A recent study conducted by researchers at Autonomous University Barcelona in Spain has examined the effects of bulk lysis procedures on target cell population counts in the field of life science. The study found that while bulk lysis assays allow for the analysis of large numbers of cells required for high-sensitivity measurable residual disease detection, they are associated with significant cell loss and potential over or underestimation of rare cells. The researchers compared bulk lysis protocols with minimal sample perturbation protocols and found that the latter better preserved the native cellular state and avoided significant cell loss. The study suggests that efforts should be made to improve bulk lysis solution reagents to obtain more accurate cell counts. [Extracted from the article]

New research from the Institute of Biomedical Chemistry in Moscow, Russia suggests that combining new therapeutics with all-trans-retinoic acid (ATRA) could improve the effectiveness of acute myeloid leukemia (AML) treatment. The study used transcriptomic profiling to identify key targets that can enhance the therapeutic effect of ATRA. The researchers found that cyclin-dependent kinase 6 (CDK6), tumor necrosis factor alpha (TNF-alpha), and transcriptional repressor CUX1 were key regulators of the molecular response to ATRA treatment in different cell lines. The study also proposed that combining ATRA with a CDK6 inhibitor (palbociclib) could be an alternative approach for AML treatment. [Extracted from the article]

A study conducted at Kunming University in Yunnan, China, has investigated the potential of Ginsenoside Rg1, a compound found in the Panax genus, as a treatment for beta-thalassemia. The study found that Rg1 increased the expression of fetal hemoglobin (HbF) without negatively affecting cell proliferation or differentiation. These findings suggest that Rg1 could be a safer alternative to traditional treatments for beta-thalassemia, such as Hydroxyurea. However, further research is needed to confirm the therapeutic efficacy of Rg1 and understand its underlying mechanisms. [Extracted from the article]

A recent report from Shanghai Ocean University in China discusses the regulation of the transcription factor NFE2 in myeloproliferative neoplasm (MPN) patients. The study aimed to explore the elements and molecular mechanisms involved in the transcriptional regulation of NFE2. The researchers identified three enhancers that regulate NFE2 transcription and found that an enhancer lncRNA positively regulates NFE2 expression and suppresses the proliferation of K562 cells. This research provides insights into the molecular mechanisms underlying leukemia and may contribute to the development of new therapeutic strategies. [Extracted from the article]

A recent study conducted by researchers at Macau University of Science & Technology in China has shed light on the potential targets of a cell differentiation agent called CDA-II in the treatment of chronic myeloid leukemia (CML). The study utilized gene expression analysis and experimental validation to identify differentially expressed genes and construct a co-expression network of long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs). The results indicated that CDA-II inhibits the proliferation and induces apoptosis in K562 cells, and identified several pathways and lncRNAs that may be involved in its biological effects. This research provides valuable insights into the mechanism of action of CDA-II and may contribute to the discovery of new therapeutic targets for CML. [Extracted from the article]

New research from Shandong University in China explores the potential of combining the RNA polymerase I inhibitor CX-5461 with the tyrosine kinase inhibitor imatinib for the treatment of tyrosine kinase inhibitor-resistant chronic myeloid leukemia. The study found that CX-5461 at a specific concentration enhanced the pro-apoptotic effect of imatinib in a p53-deficient leukemia cell line. The upregulated expression of the kinesin family member 1B (KIF1B) gene was identified as a potential mechanism for this effect. However, the regulation of KIF1B expression by the combination of imatinib and CX-5461 was not observed in all leukemic cell lines, suggesting a need for further investigation. The study suggests that the synergistic interaction between CX-5461 and imatinib may have clinical value in treating tyrosine kinase inhibitor-resistant chronic myeloid leukemia. [Extracted from the article]

A recent report from the Medical University of Warsaw in Poland discusses the findings of a study on cancer. The researchers synthesized nine derivatives, including five brominated compounds, and confirmed their structures using various techniques. These compounds were then tested on four different cancer cell lines and healthy human keratocytes. Two of the newly developed derivatives showed selective action towards chronic myelogenous leukemia cells and no toxic effects on healthy cells. The compounds were found to have pro-oxidative effects and increase reactive oxygen species in cancer cells, leading to apoptosis. Additionally, one of the compounds showed moderate antibacterial activity against Gram-positive strains. For more information, readers can refer to the International Journal of Molecular Sciences. [Extracted from the article]

A recent research study conducted by the Research Institute of Fundamental and Clinical Immunology in Novosibirsk, Russia, explores the role of tumor necrosis factor-alpha (TNF-a) signaling in cellular responses. The study focuses on the two TNF receptors, TNFR1 and TNFR2, and their impact on gene expression patterns in human K562 cell lines. The findings reveal distinct transcriptional profiles in cells lacking TNFR1 or TNFR2, highlighting the unique contributions of these receptors to TNF-a signaling. The study provides valuable insights into the mechanisms of TNF-a signaling and its potential implications for targeted therapeutic strategies. [Extracted from the article]

A study conducted by researchers at Pontifical University Javeriana in Bogota, Colombia, explored the potential of Petiveria alliacea extracts to modulate the metabolism of K562 myeloid leukemia cells. The study found that the extract reduced cell proliferation and caused alterations in the metabolism of the treated cells. In vitro assays confirmed that the extract decreased oxygen consumption rate and intracellular ATP. These findings suggest that the anti-tumor activity of the extract is attributed to its effects on cell proliferation and growth. The study provides preliminary insights into the mechanism of action of Petiveria alliacea on cancer cells. [Extracted from the article]

A recent report from the Federal University Sao Paulo discusses research on necroptosis, a form of cell death. The study focused on the effects of Artemisia vulgaris (AV) hydroalcoholic extract on breast cancer cells, chronic myeloid leukemia cells, and fibroblasts. The researchers found that the extract decreased cell viability and induced cell death primarily through late apoptosis and necrosis. The study suggests that these effects may be related to specific compounds found in the extract. The research was funded by various organizations and has been peer-reviewed. [Extracted from the article]

A recent report from the Shanghai Blood Center in China discusses the use of CRISPR/Cas9 gene editing technology to create knockout (KO) cell lines for the Vel antigen gene in K562 cells. The Vel- phenotype is a rare blood group, and this research aimed to develop a more efficient method for identifying this phenotype. The study successfully generated KO Vel blood group gene cells and induced erythroid differentiation in these edited cells using hemin. This research provides a potential tool for transfusion applications and contributes to the understanding of genomic editing of erythroid antigens. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Anhui Medical University in Beijing, China, has identified a common gene mutation, STK10, in patients with acquired pure red cell aplasia (PRCA). The mutation was found to reduce the expression of mRNA and protein in the bone marrow of affected patients. The research also revealed that the STK10 mutation affects the ribosome biosynthesis pathway, leading to abnormal erythropoiesis. These findings provide insight into the pathogenesis of PRCA and may contribute to the development of precise diagnosis and potential therapeutic targets for the condition. [Extracted from the article]

Researchers from Shanxi Medical University in China have conducted a study on chronic myeloid leukemia (CML) to investigate the expression and role of the protein CSE1L in this disease. The study found that CSE1L was highly expressed in bone marrow granulocytes of CML patients and that its knockdown inhibited cell proliferation, induced cell cycle arrest, and promoted apoptosis in CML cells. The researchers also observed changes in the expression of proteins involved in the AMPK/mTOR signaling pathway. These findings suggest that CSE1L plays a crucial role in the survival and growth of CML cells and may have implications for the treatment of CML patients. [Extracted from the article]

A recent report from researchers at Guizhou University in China discusses the synthesis and biological assessment of novel anticancer agents. The researchers designed a series of compounds containing penta-heterocycles scaffold and tested their antiproliferative activity against A549 and K562 cells. Compound 10b was found to be the most potent derivative, with significant antiproliferative effects. Mechanism investigation and docking studies revealed that compound 10b induced apoptosis and growth arrest in the tested cells, and it also modulated the EGFR and p53-MDM2 mediated pathway. This research provides valuable insights into the development of potential anticancer drugs. [Extracted from the article]

A study conducted by researchers from the University of Health Sciences in Hokkaido, Japan, has found that the overexpression of p-glycoprotein in the chronic myelogenous leukemia cell line K562/ADM leads to drug resistance. The study focused on the gene SLC25A40, which was found to be up-regulated in K562/ADM cells and was associated with increased cell proliferation and drug resistance to doxorubicin. The findings suggest that targeting SLC25A40 could be a potential strategy for overcoming drug resistance in leukemia treatment. The research was supported by the Health Sciences University of Hokkaido and has been peer-reviewed. [Extracted from the article]

Keywords: Antigen-Presenting Cells; Antigens; Artificial Antigen-Presenting Cells; Autoimmune Diseases and Conditions; Autoimmunity; Bioengineering; Biological Factors; Biomedical Engineering; Biomedicine; Biotechnology; Cancer; Cytoplasmic Structures; Dendritic Cells; Drugs and Therapies; Erythroid Precursor Cells; Exosomes; Gene Therapy; Genetics; Health and Medicine; Immune System Diseases and Conditions; Immunology; Immunotherapy; K562 Cells; Mononuclear Phagocyte System; Oncology; Organelles; Patent Application; Peptides; Proteins; Proteomics; Stem Cell Research; Transport Vesicles; Tumor Cell Line; Tumors EN Antigen-Presenting Cells Antigens Artificial Antigen-Presenting Cells Autoimmune Diseases and Conditions Autoimmunity Bioengineering Biological Factors Biomedical Engineering Biomedicine Biotechnology Cancer Cytoplasmic Structures Dendritic Cells Drugs and Therapies Erythroid Precursor Cells Exosomes Gene Therapy Genetics Health and Medicine Immune System Diseases and Conditions Immunology Immunotherapy K562 Cells Mononuclear Phagocyte System Oncology Organelles Patent Application Peptides Proteins Proteomics Stem Cell Research Transport Vesicles Tumor Cell Line Tumors 53 53 1 10/03/23 20231002 NES 231002 2023 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A patent application by the inventors KIM, Su Eon (Yongin-si, KR); KIM, Tai Gyu (Seoul, KR); SOHN, Hyun Jung (Seoul, KR), filed on April 4, 2023, was made available online on September 14, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "The present invention uses immunological exosomes secreted from artificial antigen-presenting cells which express HLA and co-stimulatory molecules to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.". [Extracted from the article]

Keywords for this news article include: Prahran, Australia, Australia and New Zealand, Acute-Phase Proteins, Beta-Globulins, Blood Proteins, Carrier Proteins, Cell Nucleus, Cell Surface Receptors, Cellular Structures, Chromosomes, Drugs and Therapies, Erythroid Precursor Cells, Genetics, Health and Medicine, Intracellular Space, Intranuclear Space, Iron-Binding Proteins, K562 Cells, Membrane Proteins, Pharmaceuticals, Pharmacology, Proteins, Therapy, Transferrin, Transferrin Receptors, Transferrin-Binding Proteins, Baker Heart and Diabetes Institute. Keywords: Prahran; Australia; Australia and New Zealand; Acute-Phase Proteins; Beta-Globulins; Blood Proteins; Carrier Proteins; Cell Nucleus; Cell Surface Receptors; Cellular Structures; Chromosomes; Drugs and Therapies; Erythroid Precursor Cells; Genetics; Health and Medicine; Intracellular Space; Intranuclear Space; Iron-Binding Proteins; K562 Cells; Membrane Proteins; Pharmaceuticals; Pharmacology; Proteins; Therapy; Transferrin; Transferrin Receptors; Transferrin-Binding Proteins EN Prahran Australia Australia and New Zealand Acute-Phase Proteins Beta-Globulins Blood Proteins Carrier Proteins Cell Nucleus Cell Surface Receptors Cellular Structures Chromosomes Drugs and Therapies Erythroid Precursor Cells Genetics Health and Medicine Intracellular Space Intranuclear Space Iron-Binding Proteins K562 Cells Membrane Proteins Pharmaceuticals Pharmacology Proteins Therapy Transferrin Transferrin Receptors Transferrin-Binding Proteins 1106 1106 1 09/19/23 20230922 NES 230922 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Membrane Proteins - Cell Surface Receptors are discussed in a new report. [Extracted from the article]

Overexpression of XK in these cells redistributed VPS13A to the biosynthetic XK pool in the ER but not to PM localized XK. When tagged VPS13A was overexpressed in hemin treated K562 cells, robust formation of ER-PM contacts positive for VPS13A were observed and their formation was abolished in XK KO cells. VPS13A binds XK, suggesting a model in which VPS13A forms a lipid transport bridge between the ER and the plasma membrane (PM) where XK resides. [Extracted from the article]

Keywords: Apoptosis; Cell Line; Cellular Physiology; Erythroid Precursor Cells; Health and Medicine; K562 Cells; Semicarbazides; Semicarbazones; Sulfur Compounds; Thiosemicarbazones EN Apoptosis Cell Line Cellular Physiology Erythroid Precursor Cells Health and Medicine K562 Cells Semicarbazides Semicarbazones Sulfur Compounds Thiosemicarbazones 426 426 1 08/28/23 20230831 NES 230831 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on apoptosis is the subject of a new report. Apoptosis, Cell Line, Cellular Physiology, Erythroid Precursor Cells, Health and Medicine, K562 Cells, Semicarbazides, Semicarbazones, Sulfur Compounds, Thiosemicarbazones The data obtained from the present study showed morphological changes resulting from apoptosis and cell cycle arrest in Sub G1 in the presence of phosphatidylserine in the outer leaflet of the cell membrane due to treatment with thiosemicarbazone compound. [Extracted from the article]

Keywords for this news article include: Islamic Azad University, Marvdasht, Iran,, Genetics, K562 Cells, Tumor Cell Line, Erythroid Precursor Cells. Keywords: Erythroid Precursor Cells; Genetics; K562 Cells; Tumor Cell Line EN Erythroid Precursor Cells Genetics K562 Cells Tumor Cell Line 1084 1084 1 08/07/23 20230807 NES 230807 2023 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New study results on erythroid precursor cells have been published. [Extracted from the article]

Keywords for this news article include: Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Moscow, Russia, Eurasia, Genetics, K562 Cells, Erythroid Precursor Cells. Keywords: Erythroid Precursor Cells; Genetics; K562 Cells EN Erythroid Precursor Cells Genetics K562 Cells 346 346 1 06/26/23 20230630 NES 230630 2023 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Research findings on erythroid precursor cells are discussed in a new report. [Extracted from the article]

Keywords: Calcium-Activated Potassium Channels; Cancer; Carrier Proteins; Chronic Myeloid Leukemia; Erythroid Precursor Cells; Health and Medicine; Hematology; Ion Channels; K562 Cells; Leukemia; Membrane Glycoproteins; Membrane Proteins; Membrane Transport Proteins; Myeloid Leukemia; Oncology; Potassium Channels EN Calcium-Activated Potassium Channels Cancer Carrier Proteins Chronic Myeloid Leukemia Erythroid Precursor Cells Health and Medicine Hematology Ion Channels K562 Cells Leukemia Membrane Glycoproteins Membrane Proteins Membrane Transport Proteins Myeloid Leukemia Oncology Potassium Channels 490 490 1 06/19/23 20230620 NES 230620 2023 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on chronic myeloid leukemia is the subject of a new report. Calcium-Activated Potassium Channels, Cancer, Carrier Proteins, Chronic Myeloid Leukemia, Erythroid Precursor Cells, Health and Medicine, Hematology, Ion Channels, K562 Cells, Leukemia, Membrane Glycoproteins, Membrane Proteins, Membrane Transport Proteins, Myeloid Leukemia, Oncology, Potassium Channels. [Extracted from the article]

Erythroid Precursor Cells, Erythropoiesis, Health and Medicine, Hematology, K562 Cells Keywords: Erythroid Precursor Cells; Erythropoiesis; Health and Medicine; Hematology; K562 Cells EN Erythroid Precursor Cells Erythropoiesis Health and Medicine Hematology K562 Cells 117 117 1 06/19/23 20230620 NES 230620 2023 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New study results on erythropoiesis have been published. [Extracted from the article]

Discussion of Related Art "Naive antigen-specific T cells may be directly stimulated by antigen-pulsed mature dendritic cells (DCs). Keywords: Antigen-Presenting Cells; Artificial Antigen-Presenting Cells; Bioengineering; Biomedical Engineering; Biomedicine; Biotechnology; Cancer; Catholic University of Korea Industry-Academic Cooperation Foundation; Cytoplasmic Structures; Dendritic Cells; Drugs and Therapies; Erythroid Precursor Cells; Exosomes; Gene Therapy; Health and Medicine; Immune System; Immunology; Immunotherapy; K562 Cells; Mononuclear Phagocyte System; Oncology; Organelles; Peptides; Proteins; Proteomics; Stem Cell Research; Transport Vesicles; Tumor Cell Line; Tumors EN Antigen-Presenting Cells Artificial Antigen-Presenting Cells Bioengineering Biomedical Engineering Biomedicine Biotechnology Cancer Catholic University of Korea Industry-Academic Cooperation Foundation Cytoplasmic Structures Dendritic Cells Drugs and Therapies Erythroid Precursor Cells Exosomes Gene Therapy Health and Medicine Immune System Immunology Immunotherapy K562 Cells Mononuclear Phagocyte System Oncology Organelles Peptides Proteins Proteomics Stem Cell Research Transport Vesicles Tumor Cell Line Tumors 130 130 1 06/05/23 20230608 NES 230608 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Catholic University of Korea Industry-Academic Cooperation Foundation (Seoul, South Korea) has been issued patent number 11649436, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. In particular, mesenchymal stem cells, neural stem cells, embryonic stem cells, umbilical cord blood-derived cells, and chronic myelogenous leukemia K562 cell lines have been used for this purpose because they do not express endogenous HLA class I and II molecules. [Extracted from the article]

Keywords: Apoptosis; Bone Marrow; Bone Research; Cancer; Caspase; Cellular Physiology; Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Drugs and Therapies; Enzyme Inhibitors; Enzymes and Coenzymes; Erythroid Precursor Cells; Health and Medicine; Hematology; K562 Cells; Leukemia; Myeloid Leukemia; Oncology; Tyrosine Kinase Inhibitors EN Apoptosis Bone Marrow Bone Research Cancer Caspase Cellular Physiology Chronic Myelogenous Leukemia Chronic Myeloid Leukemia Drugs and Therapies Enzyme Inhibitors Enzymes and Coenzymes Erythroid Precursor Cells Health and Medicine Hematology K562 Cells Leukemia Myeloid Leukemia Oncology Tyrosine Kinase Inhibitors 265 265 1 05/29/23 20230530 NES 230530 2023 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in chronic myeloid leukemia. Cell viability assay revealed that compound DBH2 exhibited the potent inhibitory activity on the proliferation of CML K562 cells and TKI resistant K562 cells. [Extracted from the article]

In the present study, we produced and characterized K562 cellular clones that, unlike the original K562 cell line, stably produced high levels of alpha-globin protein. Keywords: Ferrara; Italy; Europe; Biomarkers; Blood Proteins; Diagnostics and Screening; Erythroid Precursor Cells; Genetics; Globins; Health and Medicine; Hemeproteins; Hemoglobin Subunits; K562 Cells; Proteins; alpha-Globins EN Ferrara Italy Europe Biomarkers Blood Proteins Diagnostics and Screening Erythroid Precursor Cells Genetics Globins Health and Medicine Hemeproteins Hemoglobin Subunits K562 Cells Proteins alpha-Globins 1873 1873 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Diagnostics and Screening - Biomarkers. [Extracted from the article]

As expected, the obtained clones had a tendency to undergo apoptosis that was proportional to the accumulation of a-globin, confirming the pivotal role of a-globin accumulation in damaging erythroid cells." Keywords: Biomarkers; Diagnostics and Screening; Erythroid Precursor Cells; Genetics; Globins; Health and Medicine; Hemeproteins; K562 Cells; Proteins EN Biomarkers Diagnostics and Screening Erythroid Precursor Cells Genetics Globins Health and Medicine Hemeproteins K562 Cells Proteins 7609 7609 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on biomarkers is now available. [Extracted from the article]

Upon treatment with convallatoxin, the proliferation of K562 cells was inhibited, the cells were arrested at the S and G2/M phases, and cell apoptosis was significantly induced. Keywords: Hefei; People's Republic of China; Asia; Apoptosis; Caspase; Cell Proliferation; Cellular Physiology; Enzymes and Coenzymes; Erythroid Precursor Cells; Health and Medicine; K562 Cells EN Hefei People's Republic of China Asia Apoptosis Caspase Cell Proliferation Cellular Physiology Enzymes and Coenzymes Erythroid Precursor Cells Health and Medicine K562 Cells 1839 1839 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Cellular Physiology - Apoptosis have been presented. [Extracted from the article]

Megakaryocyte markers expression and phenotype alteration of nanocurcumin-treated K562 cells have been detected by flow cytometry and microscopy imaging. Keywords: Biomarkers; Diagnostics and Screening; Erythroid Precursor Cells; Genetics; Health and Medicine; K562 Cells; Nanotechnology EN Biomarkers Diagnostics and Screening Erythroid Precursor Cells Genetics Health and Medicine K562 Cells Nanotechnology 2023 FEB 10 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New study results on biomarkers have been published. K562 cells are typical Chronic Myelogenous Leukemia (CML) cells that are resistant to apoptosis and express the bcr-abl fusion gene. [Extracted from the article]